THE SENATE

S.B. NO.

738

THIRTY-FIRST LEGISLATURE, 2021

 

STATE OF HAWAII

 

 

 

 

 

 

A BILL FOR AN ACT

 

 

relating to schedule i substances.

 

 

BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF HAWAII:

 


SECTION 1. Chapter 321, Hawaii Revised Statutes, is amended by adding a new section to be appropriately designated and to read as follows:

"321-   Designated treatment centers; psilocybin. (a) The department shall establish designated treatment centers for the therapeutic administration of psilocybin and psilocyn.

(b) The department shall adopt rules in accordance with chapter 91 necessary to implement this section."

SECTION 2. Section 329-14, Hawaii Revised Statutes, is amended by amending subsection (d) to read as follows:

"(d) Any material, compound, mixture, or preparation that contains any quantity of the following hallucinogenic substances, their salts, isomers, and salts of isomers, unless specifically excepted, whenever the existence of these salts, isomers, and salts of isomers is possible within the specific chemical designation:

(1) Alpha-ethyltryptamine (AET);

(2) 2,5-dimethoxy-4-ethylamphetamine (DOET);

(3) 2,5-dimethoxyamphetamine (2,5-DMA);

(4) 3,4-methylenedioxy amphetamine;

(5) 3,4-methylenedioxymethamphetamine (MDMA);

(6) N-hydroxy-3,4-methylenedioxyamphetamine (N-hydroxy-MDA);

(7) 3,4-methylenedioxy-N-ethylamphetamine (MDE);

(8) 5-methoxy-3,4-methylenedioxy-amphetamine;

(9) 4-bromo-2,5-dimethoxy-amphetamine (4-bromo-2,5-DMA);

(10) 4-Bromo-2,5-dimethoxyphenethylamine (Nexus);

(11) 3,4,5-trimethoxy amphetamine;

(12) Bufotenine;

(13) 4-methoxyamphetamine (PMA);

(14) Diethyltryptamine;

(15) Dimethyltryptamine;

(16) 4-methyl-2,5-dimethoxy-amphetamine;

(17) Gamma hydroxybutyrate (GHB) (some other names include gamma hydroxybutyric acid; 4-hydroxybutyrate; 4-hydroxybutanoic acid; sodium oxybate; sodium oxybutyrate);

(18) Ibogaine;

(19) Lysergic acid diethylamide;

(20) Marijuana;

(21) Parahexyl;

(22) Mescaline;

(23) Peyote;

(24) N-ethyl-3-piperidyl benzilate;

(25) N-methyl-3-piperidyl benzilate;

[(26) Psilocybin;

(27) Psilocyn;

(28)] (26) 1-[1-(2-Thienyl) cyclohexyl] Pyrrolidine (TCPy);

[(29)] (27) Ethylamine analog of phencyclidine (PCE);

[(30)] (28) Pyrrolidine analog of phencyclidine (PCPy, PHP);

[(31)] (29) Thiophene analog of phencyclidine (TPCP; TCP);

[(32)] (30) Gamma-butyrolactone, including butyrolactone; butyrolactone gamma; 4-butyrolactone; 2(3H)-furanone dihydro; dihydro-2(3H)furanone; tetrahydro-2-furanone; 1,2-butanolide; 1,4-butanolide; 4-butanolide; gamma-hydroxybutyric acid lactone; 3-hydroxybutyric acid lactone and 4-hydroxybutanoic acid lactone with Chemical Abstract Service number 96-48-0 when any such substance is intended for human ingestion;

[(33)] (31) 1,4 butanediol, including butanediol; butane-1,4-diol; 1,4- butylenes glycol; butylene glycol; 1,4-dihydroxybutane; 1,4- tetramethylene glycol; tetramethylene glycol; tetramethylene 1,4- diol with Chemical Abstract Service number 110-63-4 when any such substance is intended for human ingestion;

[(34)] (32) 2,5-dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7), its optical isomers, salts, and salts of isomers;

[(35)] (33) N-benzylpiperazine (BZP; 1-benzylpiperazine) its optical isomers, salts, and salts of isomers;

[(36)] (34) 1-(3-trifluoromethylphenyl)piperazine (TFMPP), its optical isomers, salts, and salts of isomers;

[(37)] (35) Alpha-methyltryptamine (AMT), its isomers, salts, and salts of isomers;

[(38)] (36) 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT), its isomers, salts, and salts of isomers;

[(39)] (37) Salvia divinorum;

[(40)] (38) Salvinorin A;

[(41)] (39) Divinorin A;

[(42)] (40) 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DIPT) (some trade or other names: 5-methoxy-3-[2-(dimethylamino)ethyl]indole; 5-MeO-DMT);

[(43)] (41) 2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C-E);

[(44)] (42) 2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C-D);

[(45)] (43) 2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C-C);

[(46)] (44) 2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (2C-I);

[(47)] (45) 2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-2);

[(48)] (46) 2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-4);

[(49)] (47) 2-(2,5-Dimethoxyphenyl)ethanamine (2C-H);

[(50)] (48) 2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine (2C-N);

[(51)] (49) 2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine (2C-P);

[(52)] (50) 2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine, its optical, positional, and geometric isomers, salts, and salts of isomers (Other names: 25I-NBOMe; 2C-I-NBOMe; 25I; Cimbi-5);

[(53)] (51) 2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine, its optical, positional, and geometric isomers, salts, and salts of isomers (Other names: 25C-NBOMe; 2C-C-NBOMe; 25C; Cimbi-82); and

[(54)] (52) 2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine, its optical, positional, and geometric isomers, salts, and salts of isomers (Other names: 25B-NBOMe; 2C-B-NBOMe; 25B; Cimbi-36)."

SECTION 3. (a) The governor shall establish and convene a psilocybin review panel to review and assess the effects of this Act.

(b) The review panel shall consist of:

(1) The governor or the governor's designee, who shall serve as the chairperson of the panel;

(2) The director of health or the director's designee;

(3) The director of public safety or the director's designee;

(4) The chairperson of the house of representatives standing committee on corrections, military, and veterans or the chairperson's designee;

(5) The chairperson of the house of representatives standing committee on health, human services, and homelessness or the chairperson's designee;

(6) The chairperson of the senate standing committee on health or the chairperson's designee; and

(7) The chairperson of the senate standing committee on public safety, intergovernmental, and military affairs or the chairperson's designee.

(c) The review panel shall submit a report to the legislature, including any proposed legislation, no later than twenty days prior to the convening of the regular sessions of 2022, 2023, 2024, 2025, and 2026.

(d) The review panel shall cease to exist on July 1, 2026.

SECTION 4. Statutory material to be repealed is bracketed and stricken. New statutory material is underscored.

SECTION 5. This Act shall take effect upon its approval.

 

INTRODUCED BY:

_____________________________

 

 


 


 

Report Title:

Psilocybin; Psilocyn; Therapeutic Administration; Decriminalization

 

Description:

Removes psilocybin and psilocyn from the list of Schedule I substances. Requires the Department of Health to establish designated treatment centers for the therapeutic administration of psilocybin and psilocyn. Establishes a review panel to review and assess the effects of this measure.

 

 

 

The summary description of legislation appearing on this page is for informational purposes only and is not legislation or evidence of legislative intent.